Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder that severely jeopardizes the health of aging populations all over the world. According to the amyloid cascade hypothesis, the pathological progression of AD is associated with the formation of amyloid plaques in the brain, resulting from the aggregation of amyloid-β (Aβ) peptides. Over the past few years, vast efforts have been dedicated to the development of amyloid probes and inhibitors for the diagnosis and effective treatment of AD. We review here recent advancements in luminescent probes for the detection of Aβ peptide and fibrils, and the current development of small molecule inhibitors of Aβ aggregation. We also highlight the key features in each specific example, as well as review new ideas and strategies that are crucial for researchers in this field.
Keywords: Aggregation inhibitor, Alzheimer’s disease, beta-amyloid, luminescent probe, therapeutics agents, cholinergic neurons, trauma, amyloid cascade.
Current Alzheimer Research
Title:Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation
Volume: 9 Issue: 7
Author(s): Dik-Lung Ma, Daniel Shiu-Hin Chan, Victor Pui-Yan Ma, Ka-Ho Leung, Hai-Jing Zhong and Chung-Hang Leung
Affiliation:
Keywords: Aggregation inhibitor, Alzheimer’s disease, beta-amyloid, luminescent probe, therapeutics agents, cholinergic neurons, trauma, amyloid cascade.
Abstract: Alzheimer’s disease (AD) is a neurodegenerative disorder that severely jeopardizes the health of aging populations all over the world. According to the amyloid cascade hypothesis, the pathological progression of AD is associated with the formation of amyloid plaques in the brain, resulting from the aggregation of amyloid-β (Aβ) peptides. Over the past few years, vast efforts have been dedicated to the development of amyloid probes and inhibitors for the diagnosis and effective treatment of AD. We review here recent advancements in luminescent probes for the detection of Aβ peptide and fibrils, and the current development of small molecule inhibitors of Aβ aggregation. We also highlight the key features in each specific example, as well as review new ideas and strategies that are crucial for researchers in this field.
Export Options
About this article
Cite this article as:
Ma Dik-Lung, Shiu-Hin Chan Daniel, Pui-Yan Ma Victor, Leung Ka-Ho, Zhong Hai-Jing and Leung Chung-Hang, Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation, Current Alzheimer Research 2012; 9 (7) . https://dx.doi.org/10.2174/156720512802455377
DOI https://dx.doi.org/10.2174/156720512802455377 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Redox Status in Periodontal and Systemic Inflammatory Conditions Including Associated Neoplasias: Antioxidants as Adjunctive Therapy?
Infectious Disorders - Drug Targets Polysaccharide-Based Nanobiomaterials as Controlled Release Systems for Tissue Engineering Applications
Current Pharmaceutical Design The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) Glaucoma Disease: A Survey
Current Medical Imaging Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design Therapeutic Potential of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors for the Treatment of Retinal and Eye Diseases
CNS & Neurological Disorders - Drug Targets Novel Anticoagulants vs Warfarin for Stroke Prevention in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Sex Differences in Oxidative Stress Biomarkers
Current Drug Targets Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement
Current Pharmaceutical Design Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Current Alzheimer Research Impact of Tobacco Smoking on Lipid Metabolism, Body Weight and Cardiometabolic Risk
Current Pharmaceutical Design Utilization of the DaT-SCAN SPECT in the Diagnosis of Parkinson's Disease in Older Subjects
Letters in Drug Design & Discovery Ivabradine: Cardiovascular Effects
Recent Patents on Cardiovascular Drug Discovery Serum Arylsulfatase and Acid Phosphatase Activity in Patients with Metabolic Syndrome as a Result of Oxidative Damage to Lysosomes
Protein & Peptide Letters The Role of Thrombomodulin in Atherosclerosis: From Bench to Bedside
Cardiovascular & Hematological Agents in Medicinal Chemistry Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Gene Therapy for Familial Hypercholesterolemia
Current Pharmaceutical Design An Assessment of Patients Factors Effect on Prescriber Adherence to Ischemic Stroke Secondary Prevention Guidelines
Current Reviews in Clinical and Experimental Pharmacology